Recent Updates
Recently added Catalysts
ARWR Positive Sentiment

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

Tuesday, August 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Arrowhead Pharmaceuticals has acquired a Rare Pediatric Disease Priority Review Voucher from an undisclosed third party. This voucher will be used for the Supplemental New Drug Application for plozasiran, which aims to expand its approved indication for pediatric patients. The submission is expected before the end of 2026.

Market Sentiment Analysis

POSITIVE FACTORS

  • Acquisition of FDA Priority Review Voucher enhances drug approval prospects.
  • Plozasiran's indication expansion could benefit pediatric patients.
  • Strategic move to expedite the regulatory process.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+381%
120-day peak, hindsight
Typical move
2.1%
average across 2 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
ARO-RAGE
Phase 2 · Asthma

Full Press Release Details

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has signed an agreement with an undisclosed third party to acquire a U.S. Food and Drug Administration (FDA) Rare Pediatric Disease Priority Review Voucher (PRV). The company intends to utilize the PRV for its upcoming Supplemental New Drug Application (sNDA) submission for plozasiran, anticipated before the end of 2026, to seek approval to expand the approved indication to include patients

Frequently Asked Questions

What is the purpose of the FDA Priority Review Voucher?

The FDA Priority Review Voucher is used to expedite the review process for drug applications.

What drug is Arrowhead seeking to expand with the PRV?

Arrowhead intends to expand the approved indication for plozasiran using the PRV.

When does Arrowhead plan to submit the sNDA?

The Supplemental New Drug Application for plozasiran is anticipated before the end of 2026.

Who did Arrowhead acquire the PRV from?

The third party from whom Arrowhead acquired the PRV has not been disclosed.

ShareAdd on Google
Tags: ARWR Viatris Investor Conferences Healthcare Arrowhead Pharmaceuticals FDA Plozasiran Priority Review Voucher Rare Pediatric Disease
Last updated: Aug 4, 2026

Biotech snapshot

Cash runway
$189M liquidity · $47M/mo burn
~1 mo
High dilution risk
Lead asset
ARO-RAGEPhase 2
Asthma →

Catalyst track record

+381%
best trade around ARWR's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for ARWR.

See every catalyst's timing & PoA →